Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE